lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alector, Inc.
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
April 29, 2026
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026